Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development.
* High-throughput ADME screening
* Customised ADME assays
* In silico ADME predictive modeling
* In vitro toxicology